Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Dyne Therapeutics, Inc.

NASDAQ: DYN · Life Sciences · 5 alerts · CIK 1818794

Share price
$16.70Close, Nov 16
Market cap
$3.13B
Shares outstanding
187.39MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Dyne Therapeutics, Inc. filings on SEC EDGAR ↗

4:11 PM ET 8-K
Clinical Trial Data

Dyne Therapeutics Clinical Trial Data

Dyne Therapeutics announced additional one-year clinical data from the Phase 1/2 ACHIEVE trial of z-basivarsen (DYNE-101) for myotonic dystrophy type 1 (DM1), showing sustained functional improvement in myotonia, strength, and mobility. The data showed a 3.6-second relative improvement in hand myotonia at 6 months compared to placebo and divergence from a matched natural history cohort at 12 months. The company remains on track to report topline data from its registrational expansion cohort in Q1 2027 to support a potential BLA submission for U.S. Accelerated Approval in Q3 2027.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.